
British biotech firm Centauri has secured USD 32m to advance its platform for antimicrobial resistance (AMR) research and development, which can identify and develop new antibacterial candidates designed to treat infectious diseases, Novo Holdings announces in a press release.
The capital injection comes from an investment syndicate comprising of German Boehringer Ingelheim Venture Fund, Swedish Evotec and Novo Holdings’s antibiotic efforts, the Repair Impact Fund.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app